Organon reports Q3 2026 revenue down 2%, net income up; Sun Pharma deal expected to close by early 2027

Organon & Co. reported third-quarter 2026 financial results with a 2% year-over-year decline in revenue. Net income increased and nine-month operating cash flow improved, with growth in Hadlima and Emgality offset by declines in Nexplanon and Ontruzant. The company said its transaction with Sun Pharma is expected to close by early 2027.

Detected & updated continuously · Source: Nebula